Parkinson's Disease (PD)NCT07424508
Movement State-dependent Adaptive DBS for PD
A study testing Summit RC+S in people with Parkinson's Disease (PD), run by Doris Wang, MD, PhD at 1 site in United States.
Trial summary
This is a single-center clinical study aiming to improve gait functions in patients with Parkinson's Disease (PD) by using adaptive neurostimulation to the pallidum. The investigators will use a bidirectional deep brain stimulation device with sensing and stimulation capabilities to 1) identify neural biomarkers to… Read more about this study
- Who is it for?
- Ages 21 to 75 years
- Conditions the study is for
- Parkinson's Disease (PD)
- What is being tested?
- Summit RC+S
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 6 participants
- Where
- 1 siteUnited States
- Study dates
- 4 Feb 2026to 1 Apr 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Ability to give informed consent for the study
- Subjects implanted with Summit RC+S investigational DBS system.
- Absence of significant cognitive impairment (score of 21 or greater on the Montreal Cognitive Assessment (MoCA)
- Signed informed consent
- Age 21-75
- Diagnosis of idiopathic PD with duration of motor symptoms for 3 years or greater
Show all 9Show fewer
- Patient has undergone appropriate therapy with oral medications with inadequate relief as determined by a movement disorders neurologist.
- UPDRS-III score off medication between 20 and 80 and an improvement of at least 30% in the baseline UPDRS-III on medication score, compared to the baseline off-medication score, and motor fluctuations with at least 2 hours per day of on time without dyskinesia or with non-bothersome dyskinesia. OR Patients with tremor-dominant PD (a tremor score of at least 2 on a UPDRS-III sub-score for tremor), treatment resistant, with significant functional disability despite maximal medical management
- Patients with gait impairments: slowed gait, shuffling steps, postural instability, or freezing of gait off medication.
Who cannot join
- Inability to comply with study procedures
- Patients who cannot walk (wheelchair bound)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Movement State-Dependent Adaptive Deep Brain Stimulation for Parkinson's Disease
This is a single-center clinical study aiming to improve gait functions in patients with Parkinson's Disease (PD) by using adaptive neurostimulation to the pallidum. The investigators will use a bidirectional deep brain stimulation device with sensing and stimulation capabilities to 1) identify neural biomarkers to detect the onset of walking by recording neural activities from the motor cortical areas and the globus pallidus, 2) understand the impacts of changes in DBS parameters on gait kinematics and optimize setting parameters for enhancing walking performance, 3) develop a movement state-dependent adaptive deep brain stimulation (DBS) paradigm to automatically switch stimulation settings according to different movement states (i.e., walking vs non-walking). The proposed therapy will deliver personalized neurostimulation based on individual physiological biomarkers to enhance gait function in patients with PD. 6 patients with idiopathic Parkinson's disease who have already been implanted with the Medtronic Summit RC+S device will be enrolled in this study.
Read the detailed description
This study will allow the investigators to evaluate the efficacy of a movement state-dependent adaptive deep brain stimulation paradigm to treat gait dysfunction in individuals with Parkinson's disease (PD).
While current DBS therapy improves the appendicular symptoms of PD, such as tremor and bradykinesia, it is less effective for advanced gait symptoms, which manifest as hypokinetic gait patterns, increased gait variability, asymmetry, and disturbed balance. These symptoms are debilitating and represent a major source of morbidity for patients with PD. Studies have suggested that while conventional high-frequency stimulation settings are good at treating appendicular symptoms, they may not be as effective for axial symptoms such as gait disorders. Modulating stimulation parameters, by using lower frequencies, for instance, has been shown to improve gait kinematics such as symmetry and rhythmicity. However, these settings are less effective for other symptoms and therefore come at the expense of appendicular symptom control. The overall objective of this study is to identify personalized electrophysiological signatures of movement state and gait-optimized stimulation parameters in PD patients to enable adaptive control algorithms that automatically switch from identified 'gait-optimized' settings during walking to 'other PD symptom-optimized' settings during non-walking.
This is a small, double-blinded trial, six patients with idiopathic PD and motor fluctuations who have already been implanted with the RC+S devices. The investigators will compare the overall efficacy of closed-loop (adaptive DBS) and open-loop (continuous clinical DBS) paradigms in terms of behavioral performance improvements. During this chronic movement state-dependent adaptive DBS phase, adaptive DBS and open-loop stimulation settings will be randomized for 7-day periods, and motor and gait-related measurements will be obtained from wearable devices that track movement kinematics. Patients will participate in daily, if possible, motor and gait tasks at home and are asked to fill out motor diary questionnaires to share their feedback from both motor and non-motor perspectives.
The investigators expect to successfully develop a prototype movement state-dependent adaptive DBS algorithm. They hypothesize that the embedded closed-loop, movement state-dependent adaptive DBS paradigm will improve gait function compared to the conventional open-loop approach, in which stimulation parameters remain constant, while maintaining the standard therapeutic benefits of DBS.
- Conditions
- Parkinson's Disease (PD)
- Being tested
- Summit RC+S
- Keywords
- neuromodulation, closed-loop deep brain stimulation, gait impairments, motor learning, parkinson's disease
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Summit RC+SDevice
Participants receive gait-optimized stimulation settings while walking and Parkinson's disease symptom-optimized settings during non-walking periods.
Summit RC+SDevice
Participants receive clinically-optimized open-loop deep brain stimulation ot the pallidum.
| Study group | Role | What they receive |
|---|---|---|
| Continuous (open-loop) deep brain stimulation | Active comparator | Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving open-loop deep brain stimulation. Receives: Device: Summit RC+S |
| Movement state-dependent adaptive (closed-loop) deep brain stimulation | Active comparator | Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving movement state-dependent adaptive (closed-loop) deep brain stimulation. Receives: Device: Summit RC+S |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Mini Balance Evaluation Systems Test (Mini-BESTest) Scores
Change in Mini-BESTest scores, which is a clinical balance evaluations systems test. The score range is 0-2 with higher scores indicating higher levels of physical functioning.
Measured: after each 7 day block
Change in Gait
Change in gait measurements using the wearable devices (i.e., ankle wristband Rover and STAT-ON Holter)
Measured: 14 day long-term testing period
Change in Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III scores
Change in MDS-UPDRS III score. The scale consists of 18 items that are each scored 0 to 3, making the total score out of 72 points, with higher scores indicating higher impairment.
Measured: after each 7 day block
Change in Stride Length
Change in stride length measured by Rover (a gait measurement device) and STAT-ON (a Parkinson's disease motor symptoms measurement device) with closed-loop compared to open-loop deep brain stimulation (DBS). Stride length measured in meters.
Measured: 14 day long-term testing period
Change in Stride Time
Change in stride time measured by Rover (a gait measurement device) and STAT-ON (a Parkinson's disease motor symptoms measurement device) with closed-loop compared to open-loop deep brain stimulation (DBS). Stride time measured in seconds.
Measured: 14 day long-term testing period
Change in Double Support Time
Change in stride time measured by Rover (a gait measurement device). Each gait cycle consists of two phases, where both feet are in contact with the ground, called Double Support. Double support time will be measured in seconds (i.e. amount of time both feet are in contact with the ground).
Measured: 14 day long-term testing period
Change in number of freezes
Change in number of freezes measured by STAT-ON (a Parkinson's disease motor symptoms measurement device) with closed-loop compared to open-loop deep brain stimulation (DBS).
Measured: 14 day long-term testing period
Change in number of falls
Change in number of falls measured by STAT-ON (a Parkinson's disease motor symptoms measurement device) with closed-loop compared to open-loop deep brain stimulation (DBS).
Measured: 14 day long-term testing period
Change in Activities-Specific Balance Confidence (ABC) Scale
Change in ABC Scale, which collects measures of confidence in performing various ambulatory activities without falling or experiencing a sense of unsteadiness. The score range is 0-100 with higher scores indicating higher levels of physical functioning.
Measured: once per day during 14 day long-term testing period
Secondary outcomes (2)
Change in Montreal Cognitive Assessment (MoCA) scores
Change in MoCA score. The scale consists of 30 1-point questions testing short term memory, visuospatial abilities, executive functions, attention, concentration, working memory, language, and orientation to time and place, with scores lower than 26 indicating possible cognitive impairment.
Measured: after each 7 day block
Changes in Parkinson's Disease (PD) Symptoms Questionnaire
Changes in responses to a questionnaire that collects information about PD symptoms, balance, walking, falls, and freezing of gait.
Measured: once per day during 14 day long-term testing period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2026
- Study start4 Feb 2026
- Primary completion1 Apr 2030 (estimated)
- Study completion1 Apr 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Parkinson's Disease (PD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- In a small, double-blinded trial, the investigators will compare the overall efficacy of closed-loop and open-loop paradigms in terms of behavioral performance improvements in subject-reported metrics and validated measurements from wearable devices. During the long-term movement state-dependent adaptive DBS (aDBS) phase, aDBS and open-loop constant stimulation settings will be randomized for 7-day periods, and motor and gait-related measurements will be obtained from wearable devices that track movement kinematics. At the end of each 7-day block, the research team will administer clinical tests, including the Montreal Cognitive Assessment (MoCA), Unified Parkinson's Disease Rating Scale (UPDRS) III, and the Mini Balance Evaluation Systems Test (Mini-BESTest).
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 6 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Doris Wang, MD, PhD
- Sponsor type
- University, hospital or other
- Collaborators
- Michael J. Fox Foundation for Parkinson's Research, Burroughs Wellcome
- Responsible party
- Sponsor-investigator, Doris Wang, MD, PhD, University of California, San Francisco
- Investigators
- Doris Wang, MD, PhD, Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07424508
- Sponsor's protocol ID
- 25-45335
- Status last verified
- Feb 2026
- First submitted
- 13 Feb 2026
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Little S, Pogosyan A, Neal S, Zavala B, Zrinzo L, Hariz M, Foltynie T, Limousin P, Ashkan K, FitzGerald J, Green AL, Aziz TZ, Brown P. Adaptive deep brain stimulation in advanced Parkinson disease. Ann Neurol. 2013 Sep;74(3):449-57. doi: 10.1002/ana.23951. Epub 2013 Jul 12.
PubMed 23852650Wang D, Ramesh R, Azgomi HF, Louie K, Balakid J, Marks J. At-Home Movement State Classification Using Totally Implantable Bidirectional Cortical-Basal Ganglia Neural Interface. Res Sq [Preprint]. 2025 Mar 12:rs.3.rs-6058394. doi: 10.21203/rs.3.rs-6058394/v1.
PubMed 40162212Azgomi HF, Louie KH, Bath JE, Presbrey KN, Balakid JP, Marks JH, Wozny TA, Galifianakis NB, Luciano MS, Little S, Starr PA, Wang DD. Modeling and Optimizing Deep Brain Stimulation to Enhance Gait in Parkinson's Disease: Personalized Treatment with Neurophysiological Insights. medRxiv [Preprint]. 2024 Nov 1:2024.10.30.24316305. doi: 10.1101/2024.10.30.24316305.
PubMed 39574845
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Movement State-Dependent Adaptive Deep Brain Stimulation for Parkinson's Disease
- ClinicalTrials.gov ID
- NCT07424508
- Acronym / sponsor ID
- 25-45335
- Conditions
- Parkinson's Disease (PD)
- Keywords
- neuromodulation, closed-loop deep brain stimulation, gait impairments, motor learning, parkinson's disease
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 6 participants (estimated)
- Lead sponsor
- Doris Wang, MD, PhDUniversity, hospital or other
- Collaborators
- Michael J. Fox Foundation for Parkinson's Research, Burroughs Wellcome
- Study start
- 4 Feb 2026 (actual)
- Primary completion
- 1 Apr 2030 (estimated)
- Study completion
- 1 Apr 2030 (estimated)
- First posted
- 20 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-center clinical study aiming to improve gait functions in patients with Parkinson's Disease (PD) by using adaptive neurostimulation to the pallidum. The investigators will use a bidirectional deep brain stimulation device with sensing and stimulation capabilities to 1) identify neural biomarkers to detect the onset of walking by recording neural activities from the motor cortical areas and the globus pallidus, 2) understand the impacts of changes in DBS parameters on gait kinematics and optimize setting parameters for enhancing walking performance, 3) develop a movement state-dependent adaptive deep brain stimulation (DBS) paradigm to automatically switch stimulation settings according to different movement states (i.e., walking vs non-walking). The proposed therapy will deliver personalized neurostimulation based on individual physiological biomarkers to enhance gait function in patients with PD. 6 patients with idiopathic Parkinson's disease who have already been implanted with the Medtronic Summit RC+S device will be enrolled in this study.
Detailed description
This study will allow the investigators to evaluate the efficacy of a movement state-dependent adaptive deep brain stimulation paradigm to treat gait dysfunction in individuals with Parkinson's disease (PD).
While current DBS therapy improves the appendicular symptoms of PD, such as tremor and bradykinesia, it is less effective for advanced gait symptoms, which manifest as hypokinetic gait patterns, increased gait variability, asymmetry, and disturbed balance. These symptoms are debilitating and represent a major source of morbidity for patients with PD. Studies have suggested that while conventional high-frequency stimulation settings are good at treating appendicular symptoms, they may not be as effective for axial symptoms such as gait disorders. Modulating stimulation parameters, by using lower frequencies, for instance, has been shown to improve gait kinematics such as symmetry and rhythmicity. However, these settings are less effective for other symptoms and therefore come at the expense of appendicular symptom control. The overall objective of this study is to identify personalized electrophysiological signatures of movement state and gait-optimized stimulation parameters in PD patients to enable adaptive control algorithms that automatically switch from identified 'gait-optimized' settings during walking to 'other PD symptom-optimized' settings during non-walking.
This is a small, double-blinded trial, six patients with idiopathic PD and motor fluctuations who have already been implanted with the RC+S devices. The investigators will compare the overall efficacy of closed-loop (adaptive DBS) and open-loop (continuous clinical DBS) paradigms in terms of behavioral performance improvements. During this chronic movement state-dependent adaptive DBS phase, adaptive DBS and open-loop stimulation settings will be randomized for 7-day periods, and motor and gait-related measurements will be obtained from wearable devices that track movement kinematics. Patients will participate in daily, if possible, motor and gait tasks at home and are asked to fill out motor diary questionnaires to share their feedback from both motor and non-motor perspectives.
The investigators expect to successfully develop a prototype movement state-dependent adaptive DBS algorithm. They hypothesize that the embedded closed-loop, movement state-dependent adaptive DBS paradigm will improve gait function compared to the conventional open-loop approach, in which stimulation parameters remain constant, while maintaining the standard therapeutic benefits of DBS.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- In a small, double-blinded trial, the investigators will compare the overall efficacy of closed-loop and open-loop paradigms in terms of behavioral performance improvements in subject-reported metrics and validated measurements from wearable devices. During the long-term movement state-dependent adaptive DBS (aDBS) phase, aDBS and open-loop constant stimulation settings will be randomized for 7-day periods, and motor and gait-related measurements will be obtained from wearable devices that track movement kinematics. At the end of each 7-day block, the research team will administer clinical tests, including the Montreal Cognitive Assessment (MoCA), Unified Parkinson's Disease Rating Scale (UPDRS) III, and the Mini Balance Evaluation Systems Test (Mini-BESTest).
| Arm | Type | Receives |
|---|---|---|
| Continuous (open-loop) deep brain stimulation | Active comparator | Device: Summit RC+SParkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving open-loop deep brain stimulation. |
| Movement state-dependent adaptive (closed-loop) deep brain stimulation | Active comparator | Device: Summit RC+SParkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving movement state-dependent adaptive (closed-loop) deep brain stimulation. |
Who may qualify
- Ages
- 21 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Ability to give informed consent for the study
- Subjects implanted with Summit RC+S investigational DBS system.
- Absence of significant cognitive impairment (score of 21 or greater on the Montreal Cognitive Assessment (MoCA)
- Signed informed consent
- Age 21-75
Key exclusion criteria (2 listed)
- Inability to comply with study procedures
- Patients who cannot walk (wheelchair bound)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Summit RC+SParticipants receive gait-optimized stimulation settings while walking and Parkinson's disease symptom-optimized settings during non-walking periods. | Device | Movement state-dependent adaptive (closed-loop) deep brain stimulation |
| Summit RC+SParticipants receive clinically-optimized open-loop deep brain stimulation ot the pallidum. | Device | Continuous (open-loop) deep brain stimulation |
Primary outcome
Change in Mini Balance Evaluation Systems Test (Mini-BESTest) Scores
Time frame: after each 7 day block
Change in Mini-BESTest scores, which is a clinical balance evaluations systems test. The score range is 0-2 with higher scores indicating higher levels of physical functioning.
Change in Gait
Time frame: 14 day long-term testing period
Change in gait measurements using the wearable devices (i.e., ankle wristband Rover and STAT-ON Holter)
Change in Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III scores
Time frame: after each 7 day block
Change in MDS-UPDRS III score. The scale consists of 18 items that are each scored 0 to 3, making the total score out of 72 points, with higher scores indicating higher impairment.
Change in Stride Length
Time frame: 14 day long-term testing period
Change in stride length measured by Rover (a gait measurement device) and STAT-ON (a Parkinson's disease motor symptoms measurement device) with closed-loop compared to open-loop deep brain stimulation (DBS). Stride length measured in meters.
Change in Stride Time
Time frame: 14 day long-term testing period
Change in stride time measured by Rover (a gait measurement device) and STAT-ON (a Parkinson's disease motor symptoms measurement device) with closed-loop compared to open-loop deep brain stimulation (DBS). Stride time measured in seconds.
Change in Double Support Time
Time frame: 14 day long-term testing period
Change in stride time measured by Rover (a gait measurement device). Each gait cycle consists of two phases, where both feet are in contact with the ground, called Double Support. Double support time will be measured in seconds (i.e. amount of time both feet are in contact with the ground).
Change in number of freezes
Time frame: 14 day long-term testing period
Change in number of freezes measured by STAT-ON (a Parkinson's disease motor symptoms measurement device) with closed-loop compared to open-loop deep brain stimulation (DBS).
Change in number of falls
Time frame: 14 day long-term testing period
Change in number of falls measured by STAT-ON (a Parkinson's disease motor symptoms measurement device) with closed-loop compared to open-loop deep brain stimulation (DBS).
Change in Activities-Specific Balance Confidence (ABC) Scale
Time frame: once per day during 14 day long-term testing period
Change in ABC Scale, which collects measures of confidence in performing various ambulatory activities without falling or experiencing a sense of unsteadiness. The score range is 0-100 with higher scores indicating higher levels of physical functioning.
2 secondary outcomes
Change in Montreal Cognitive Assessment (MoCA) scores
Time frame: after each 7 day block
Changes in Parkinson's Disease (PD) Symptoms Questionnaire
Time frame: once per day during 14 day long-term testing period
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
- Background: PubMed 23852650Little S, Pogosyan A, Neal S, Zavala B, Zrinzo L, Hariz M, Foltynie T, Limousin P, Ashkan K, FitzGerald J, Green AL, Aziz TZ, Brown P. Adaptive deep brain stimulation in advanced Parkinson disease. Ann Neurol. 2013 Sep;74(3):449-57. doi: 10.1002/ana.23951. Epub 2013 Jul 12.
- Background: PubMed 40162212Wang D, Ramesh R, Azgomi HF, Louie K, Balakid J, Marks J. At-Home Movement State Classification Using Totally Implantable Bidirectional Cortical-Basal Ganglia Neural Interface. Res Sq [Preprint]. 2025 Mar 12:rs.3.rs-6058394. doi: 10.21203/rs.3.rs-6058394/v1.
- Background: PubMed 39574845Azgomi HF, Louie KH, Bath JE, Presbrey KN, Balakid JP, Marks JH, Wozny TA, Galifianakis NB, Luciano MS, Little S, Starr PA, Wang DD. Modeling and Optimizing Deep Brain Stimulation to Enhance Gait in Parkinson's Disease: Personalized Treatment with Neurophysiological Insights. medRxiv [Preprint]. 2024 Nov 1:2024.10.30.24316305. doi: 10.1101/2024.10.30.24316305.
- Individual participant dataSharing planned: No
Related trials for Parkinson's Disease (PD)
RecruitingPhase 2
Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS
Parkinson's Disease, Deep Brain Stimulation
RecruitingObservational study
Parkinson's Disease in Type 1 Gaucher Disease
Parkinson Disease (PD), Type 1 Gaucher Disease
Recruiting
Ginger-PD: Ginger as a Modifier of Ghrelin Levels and Gut Function in Parkinson's Disease
REM Sleep Behavior Disorder, Parkinson s Disease
Recruiting
Effects of Vagal Nerve Stimulation on Leg Muscle Activity and Posture in Parkinson's Disease
PARKINSON DISEASE (Disorder), Parkinson's Disease (PD)
Not yet recruiting
Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD)
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Doris Wang, MD, PhD principal investigator
University of California, San Francisco
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Summit RC+S in people with Parkinson's Disease (PD), run by Doris Wang, MD, PhD at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Mini Balance Evaluation Systems Test (Mini-BESTest) Scores (time frame: after each 7 day block). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07424508, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.